Corporate Information
Zim focuses on multiple business aspects & multi-pronged growth strategy for sustained progress.
GROWTH INITIATIVES
IN CONTINUE NDDS: AS CORE OFFERING
Focus on developing new delivery solutions for generic products which
Enhance product life cycle
Increase patient convenience
Improved adherence in treatement
with priority on certain therapeutic segments.
COMMERCIALISE OTF PLATFORMS
Alternate drug delivery solution for generic pharmaceutical & nutraceutical products (prescription & OTC)
Step up direct marketing:
Hire senior marketing professionals for developing marketing partnerships in finished formulations and semi-finished products across RoW markets.
Invest in product registration & marketing partnerships that allow ZIM to capture value of brands and better margins.
Invest in R&D with focus on entering developed markets
Equipment, team, studies, processes & systems.
Facilities to develop a pipeline of products valuable to business partners & patients across markets (co-development & own new product alternatives) with specific focus on entering developed markets.
ENHANCE CAPACITY AND FLEXIBILITY IN OPERATIONS
Add small batch manufacturing (SBM) facilities for promoting the formulations business & supporting clients across markets with small but high value order quantities including technology transfer from R&D.
STRENGTHTEN R&D CENTER AND INVEST IN PRODUCT DEVELOPEMENT
Focus on developing new delivery solutions for generic products which:
Continue strengthening R&D capabilities – Increase investment in R&D as % of sales.
Acquire scientists, formulators, analysts & add higher end scientific equipment to the existing R&D centre.
Invest in various pilot, pivotal stability and BE studies (own & under co-development) to enhance development process, audit trails, dossier readiness, filings & registrations.
Partnering with non-infringing API producers for developing products to be launched in EM.
NEW R&D CENTER FOR DEVELOPED MARKETS
Hire experienced R&D professionals to lead product development, various studies, dossier readiness, filings, registration and launch of products in U.S.A / Developed Markets with expertise for product registrations from U.S.A FDA, MHRA UK, ANVISA, etc.
The OTF R&D Centre to initiate independent contract research operations for other pharmaceutical companies in regulated markets.
Invest in pilot, pivotal and bio-equivalence studies (Under Co-Development).
R&D centre to eventually launch products in Developed Markets – key target being USA (prescription and OTC products) with immediate focus being on “emerging and RoW markets”.
New Drug Delivery Platforms (MUPS, Patches etc.) to be developed at this R&D centre.
NEW REGISTRATIONS
Invest in team and processes for development of dossiers and product registration/filings across markets.
PRE FORMULATED INTERMEDIATES (PFI)
Strengthen core PFI business with focus on developing a pipeline of high margin products.
Enter into local marketing tie-ups and new partnerships in new geographies like LATAM, CIS and MENA
DIFFERENTIATED FORMULATIONS
ZIM ventured into Sri Lanka directly for differentiated formulations in FY 2011.
Products were jointly developed in consultation with Sri Lankan partners & supplied in finished dosage form, including ready to market packaging and the registrations of the product with the partner. The business in Sri Lanka grew 12x over the last 6 years from INR 10 Million in FY11 to INR 127 Million in FY17 with a CAGR of over 50%.
ZIM plans to replicate the Sri Lankan model in other regions and introduce high margin differentiated generic formulations in RoW and Emerging Markets – MENA, SA, SEA, CIS & LATAM.
Enter into marketing joint venture arrangements, partnerships, authorisations for specific markets to capture more of the value chain in terms of brand registrations and improved margins.
ORAL THIN FILMS (OTF)
Focus on new product development and product life extensions for original product manufacturers (OPMs).
Enter into long term licensing agreements with OPM and other players to co-develop their existing products in OTF format.
Plans to enter into developed markets (US, EU, JAPAN) in partnership with OPMs over time.
Register the OTF product in RoW and emerging markets under its brand and market through partnership with local players.
NEW PELLETS AND GRANUALES MANUFACTURING FACILITY
Set-up dedicated small batch manufacturing (SBM) facility for manufacturing pellets, tablets & granules to bring about.
Flexibility in manufacturing for pre-formulation and formulation for exports and,
Unlock capacity constraint in existing plant.
ENHANCING QUALITY ASSURANCE (QA) AND QUALITY CONTROL (QC)
Internal reorganisation & upgrading of certain facilities for improved audit and compliance.
Investment in equipment and more experienced manpower.
Invest in ERP for integrated software that covers operations & financial processes in line with requirements of developed markets.
BOARD OF DIRECTORS
COMPANY LEADERSHIP
Dr. Anwar S. Daud
(M.Pharm, Ph.D)
Chairman and Managing Director
Dr. Anwar Daud, PhD. (Pharmaceutical Sciences), M. Pharm. (Medicinal Chemistry) from
Nagpur University (1983), promoted ZIM in 1989.
Dr. Anwar S. Daud
(M.Pharm, Ph.D)
Chairman & Managing Director
An M. Pharm in Medicinal Chemistry and a Ph.D in Pharmaceutics, he started his Professional career in 1981 with a brief stint at IPCA Laboratories Ltd. after which he became one of the key promoters of ZIM Laboratories Ltd. which started its operations in 1990. The subsequent years tiny organization with fifteen employees to Central India’s premier pharmaceutical company making several novel formulation products at multi-locational manufacturing facilities and not only with a domestic footprint but also a presence in 26 countries spread over emerging markets in MENA, Latin America, CIS & Russia.
CloseMANAGEMENT COMMITTEE
Mr. Zulfiquar Kamal(B.Com, FCA)
Director - Finance
Mr. Zulfiquar Kamal is a chartered accountant and has been associated with the company for over 25 years.
Mr. Prakash Sapkal(B.Pharm. MBA)
Director-Operations
Mr. Prakash Sapkal is a Pharmacy graduate with post-graduation in Business Administration and has been associated with the Company for 24 years.
Mr. Vijay Fudke(B.Pharm. DMP)
Senior Vice President – Technical Services
Mr. Niraj Dhadiwal (B.Pharm. DBM)
Director - Business Development
Mr. Niraj Dhadiwal is a pharmacy graduate with a diploma in business management and has been with the company for nearly three decades.
Mr. Riaz Kamal (B.Sc. AIC)
Director - Administration
Mr. Pradeep Kataria (M.Pharm)
Senior Vice President – Operations
Mr Pradeep Kataria is a postgraduate in pharmacy with an association of more than 21 years with the organization.
OUR PRESENCE
Current Presence
Target Markets
BUSINESS MIX BREAKUP OF SALES (INR MN)
FINANCIALS
Over the last 4 years, high margin business (>50% gross margin) has seen a CAGR of 20%
(growing 1.7x) compared to a drop of 17% CAGR in the low margin business during the same period. The strategy for improving margins and consequently better return from capital employed has been driven primarily on account of:
Focused marketing efforts on direct exports of PFI.
Formulation Products.
Reducing low margin deemed exports business-particularly from Africa.
Direct bidding for higher margin products in.
Government tenders vs. bidding through third parties.
‘Commercialization’ of the OTF range of products.
STANDALONE HALF YEARLY INCOME STATEMENTS FY 2020
STANDALONE YEARLY INCOME STATEMENTS
STANDALONE YEARLY STATEMENTS OF FINANCIAL POSITION
INVESTOR REPORTS & PRESENTATIONS
ANNUAL RESULTS
QUARTERLY RESULTS
ANNUAL REPORTS
SUBSIDIARIES
SHAREHOLDING PATTERNS
POLICIES
STATUTORY COMMUNICATIONS
CORPORATE GOVERNANCE
SHAREHOLDERS UNPAID DIVIDENDS
ANNUAL RESULTS
QUARTERLY RESULTS
QUARTERLY FINANCIAL RESULTS
Quaterly Results
Quarterly Financial Results - Q4 F.Y. 2019-20
Quarterly Financial Results - Q3 F.Y. 2019-20
Quarterly Financial Results - Q2 F.Y. 2019-20
Quarterly Financial Results - Q1 F.Y. 2019-20
Quarterly Financial Results - Q4 - 2018-19
QUARTERLY FINANCIAL RESULTS - Q3 - 2018-19
QUARTERLY FINANCIAL RESULTS - Q2 - 2018-19
QUARTERLY FINANCIAL RESULTS - Q1 - 2018 - 19
QUARTERLY FINANCIAL RESULTS - Q4 - 2017 - 18
QUARTERLY FINANCIAL RESULTS - Q3 - 2017 - 18
QUARTERLY FINANCIAL RESULTS - Q2 - 2017 - 18
QUARTERLY FINANCIAL RESULTS - Q1 - 2017 - 18
QUARTERLY FINANCIAL RESULTS - Q4 - 2016 - 17
QUARTERLY FINANCIAL RESULTS - Q3 - 2016 - 17
QUARTERLY FINANCIAL RESULTS - Q2 - 2016 - 17
QUARTERLY FINANCIAL RESULTS - Q1 - 2016 - 17
ANNUAL REPORTS
ANNUAL REPORTS
We are pleased to present to you ZIM Laboratories Limited Annual Reports.
SUBSIDIARIES
ZIM Laboratories FZE Financial - 2018-19.pdf
SHAREHOLDING PATTERNS
SHAREHOLDING PATTERN
Share Holding
SHARE HOLDING PATTERN 31.03.2020
SHARE HOLDING PATTERN 31.12.2019
SHARE HOLDING PATTERN 30.09.2019
SHARE HOLDING PATTERN 30.06.2019
SHARE HOLDING PATTERN 31.03.2019
Shareholding Pattern 31.12.2018
SHARE HOLDING PATTERN 30.09.2018
SHARE HOLDING PATTERN 30.06.2018
SHAREHOLDING PATTERN 31.03.2018
SHAREHOLDING PATTERN 31.12.2017
SHAREHOLDING PATTERN 30.09.2017
SHAREHOLDING PATTERN 30.06.2017
SHAREHOLDING PATTERN 31.03.2017
SHAREHOLDING PATTERN 31.12.2016
POLICIES
POLICIES
STATUTORY COMMUNICATIONS
STATUTORY COMMUNICATIONS
2020
2019
2018
2020
2019
23(9) LODR Related Party Disclosure Sept 2019
Outcome of Board Meeting 11.11.2019
Newspaper Publication - Board Meeting 11.11.2019
Notice for Board Meeting on 11.11.2019
Outcome of Board Meeting - August 6, 2019
Notice of Board Meeting August 6, 2019
Intimation for Credit Rating
23(9) LODR Related Party Disclosure Mar 2019
Outcome of Board Meeting - May 22,2019
Notice of Board Meeting - May 22,2019
"Proceeding of EGM - March 25, 2019
"Notice of EGM - March 25, 2019
"Outcome of Board Meeting - February 22, 2019
"Outcome of Board Meeting - February 6, 2019
"Intimation for Investors' Presentation
"Notice of Board Meeting - February 6, 2019
2018
Outcome of Board Meeting - November 4, 2018
Notice of Board Meeting - November 4, 2018
Notice of Board Meeting - August 14, 2018
Intimation for Record Date Bonus & Dividend.
Intimation of AGM and Book Closure
Outcome of Board Meeting 14.08.2018
Intimation for Investors meet 05.09.2018
CORPORATE GOVERNANCE
SHAREHOLDERS UNPAID DIVIDENDS
INVESTOR CONTACT
MR. PIYUSH NIKHADE
Company Secretary and Compliance Officer
Sadoday Gyan (Ground Floor)
Opp. NADT, Nelson Square,
Nagpur – 440013
cs@zimlab.in 0712-2588070
ZULFIQUAR KAMAL
(B.Com. FCA)
Director - Finance
A chartered accountant, Zulfiquar Kamal has been associated with the company for over 25 years. He has been on the Board of Directors since 1991. With his financial acumen, refined over an experience of more than three decades, he brings to the table the financial discipline and control necessary for a growing organization like ZIM. In his current role as Director – Finance, Mr. Kamal oversees the commercial operations of the company. He envisions ZIM to be a financially efficient organization known for its operational efficiencies and technological process.
Close
NIRAJ DHADIWAL
(B.Pharm. DBM)
Director - Business Development
Mr. Niraj Dhadiwal is a pharmacy graduate with a diploma in business management and has been with the company for nearly three decades. He started his career with ZIM as a production officer in 1991, rising through ranks to his current position of Director. With his keen business mind and technical knowledge, Mr Dhadiwal has played a key role in the export-development arm of the company. His contribution to the development of overseas business stands unmatched and a testament to his foresight and ability to tap into new markets. In his current role as Director – Business Development, Mr Dhadiwal looks after the business development and marketing functions of the company. He envisions ZIM to have a global presence with innovative and differentiated products leading to good returns for all the stakeholders.
Close
PRAKASH SAPKAL
(B.Pharm. MBA)
Director-Operations
Mr. Prakash Sapkal is a Pharmacy graduate with post-graduation in Business Administration. He is associated with the Company for 24 years starting his career as Assistant Chemist. During all these years he has handled key operations in various capacities like Production Supervisor, Production Manager and Vice President – Operations. His major contribution has been in assembling a team that has brought the vision of ZIM to life.
Close
Riaz Kamal
(B.Sc. AIC)
Director - Administration
Mr. Riaz Kamal has been associated with the company since inception. His experience across these four decades extends across functions like quality control, raw material purchase, product costing and government institutional business. He has been a key player in managing the business with important contributions in the domestic institutional business, establishing and implementing policies, working processes and maintaining a disciplined and efficient workforce. In his current role as Director – Administration, Mr Riaz looks after the government institutional business and general administration including personnel and HR departments.
Close
PRADEEP KATARIA
(M.Pharm)
Senior Vice President – Operations
Mr. Pradeep Kataria is a postgraduate in pharmacy with an association of more than 21 years with the organization. Having spent early his initial professional years in the production department of Ranbaxy Limited, Mr Kataria joined ZIM as Production Supervisor in 1995. He has been a hands-on leader of the Operations team and has been involved in successful scale-ups of pellets and taste-masking technologies developed in R&D. He has also been a meticulous administrator in developing, maintaining and managing the in accordance with the high standards required for various accreditations. In his current role as Senior Vice President – Operations, Mr Kataria, with his problem-solving and administration skills, looks after day-to-day activities of the plant, including manufacturing, external audits and internal coordination amongst operational departments.
Close
Vijay Fudke
(B.Pharm. DMP)
Senior Vice President – Technical Services
Mr. Vijay Fudke is a pharmacy graduate with an association of more than 20 years with ZIM. Having spent his initial years in the field of quality control, Mr Fudke joined ZIM as a Quality Assurance (QA) Officer in 1996. He has played an instrumental role in the achievement of various accreditations by the company, such as the EU-GMP, WHO-GMP & ISO 9001:2008. In his current role as Senior Vice President – Technical Services, Mr Fudke is involved in providing clients with technical services like molecule selection for development, business expansion and high-level technical query resolution. He is also involved in the Regulatory documentation for product registration and harmonization between the customer and the internal business development teams, plant QA and R&D.
While financial growth and a strong presence in regulated markets constitute his short-term objectives, Mr Fudke’s vision is to establish ZIM as a company with differentiated superior-quality products, processes, personnel and technology
